2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details


臨床試験数 : 645 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04313166
(ClinicalTrials.gov)
March 19, 202015/3/2020Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Complete Study CMD-2019-001Amyotrophic Lateral SclerosisDrug: Cu(II)ATSMCollaborative Medicinal Development Pty LimitedNULLCompleted18 Years75 YearsAll55Phase 2Australia
2NCT04082832
(ClinicalTrials.gov)
September 30, 20192/9/2019CuATSM Compared With Placebo for Treatment of ALS/MNDA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Cu(II)ATSM in Patients With Amyotrophic Lateral Sclerosis/Motor Neuron DiseaseAmyotrophic Lateral SclerosisDrug: Cu(II)ATSM;Drug: PlacebosCollaborative Medicinal Development Pty LimitedNULLRecruiting18 Years75 YearsAll80Phase 2/Phase 3Australia
3NCT03136809
(ClinicalTrials.gov)
January 18, 201828/4/2017ALS Treatment Extension StudyA Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Completed Study CMD-2016-001Amyotrophic Lateral SclerosisDrug: Cu(II)ATSMCollaborative Medicinal Development Pty LimitedNULLActive, not recruiting18 Years75 YearsAll28Phase 1/Phase 2Australia
4NCT02870634
(ClinicalTrials.gov)
November 16, 201610/8/2016Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MNDA Phase 1 Single and Multiple Dose Escalation and Pharmacokinetic Study of Cu(II)ATSM Administered Orally to Patients With Amyotrophic Lateral Sclerosis/Motor Neuron DiseaseAmyotrophic Lateral Sclerosis;Motor Neuron DiseaseDrug: Cu(II)ATSMCollaborative Medicinal Development Pty LimitedNULLCompleted18 Years75 YearsAll50Phase 1Australia